NEW YORK (GenomeWeb News) – Asuragen said yesterday that it has raised $18.5 million in Series B financing.
The funding adds to $49 million that the company raised in a Series A round last year.
Investors in the Series B round include PTV Sciences, a new investor, as well as previous investors Telegraph Hill Partners and Growth Capital Partners.
Asuragen is a spinoff of Ambion that was formed after Applied Biosystems acquired Ambion's RNA business in March 2006. It includes Ambion's former diagnostics and services division as well as a discovery group.
In addition to diagnostic research, Asuragen is developing microRNAs as cancer therapeutics and is conducting pre-clinical development of its lead candidates.